Treatments and vaccines for COVID-19
Table of contents
Medicines authorised in the European Union (EU) to treat or prevent COVID-19, following a scientific evaluation by the European Medicines Agency (EMA). It provides details on the other potential treatments and vaccines that EMA is evaluating or has provided support to during research and development.
|
COVID-19 vaccines under investigation, evaluation and authorised for use in the EU |
COVID-19 treatments under investigation, evaluation and authorised for use in the EU |
|
Monitoring of COVID-19 medicines How EMA is monitoring safety and effectiveness of COVID-19 medicines. |
Transparency: exceptional measures for COVID-19 medicines EMA's exceptional measures to ensure its regulatory activities in relation to COVID-19 medicines are as transparent as possible. |
EMA is assessing all applications for COVID-19 treatments and vaccines under the minimum timeframe necessary to allow a thorough evaluation of the medicine's benefits and risks, in accordance with its usual standards for quality, safety and efficacy.
EMA holds press briefings to announce breaking news and explain its latest scientific work in tackling the COVID-19 pandemic:
- EMA regular press briefing on public health emergencies (24/11/2022)
- EMA regular press briefing on COVID-19 and monkeypox (26/10/2022)
- EMA regular press briefing on COVID-19 and monkeypox (20/09/2022)
- EMA regular press briefing on COVID-19 and monkeypox (02/09/2022)
- EMA regular press briefing on COVID-19 (07/07/2022)
- EMA regular press briefing on COVID-19 (02/06/2022)
- EMA regular press briefing on COVID-19 (05/05/2022)
- EMA regular press briefing on COVID-19 (17/03/2022)
- EMA regular press briefing on COVID-19 (03/03/2022)
- EMA regular press briefing on COVID-19 (17/02/2022)
- EMA regular press briefing on COVID-19 (03/02/2022)
- EMA regular press briefing on COVID-19 (18/01/2022)
- EMA regular press briefing on COVID-19 (11/01/2022)
- EMA regular press briefing on COVID-19 (21/12/2021)
- EMA regular press briefing on COVID-19 (09/12/2021)
- EMA regular press briefing on COVID-19 (18/11/2021)
- EMA regular press briefing on COVID-19 (04/11/2021)
- EMA regular press briefing on COVID-19 (21/10/2021)
- EMA press briefing to inform on CHMP discussion on booster doses (05/10/2021)
- EMA regular press briefing on COVID-19 (23/09/2021)
- EMA regular press briefing on COVID-19 (09/09/2021)
- EMA regular press briefing on COVID-19 (15/07/2021)
- EMA regular press briefing on COVID-19 (01/07/2021)
- EMA regular press briefing on COVID-19 (17/06/2021)
- EMA regular press briefing on COVID-19 (28/05/2021)
- First EMA regular press briefing on COVID-19 (12/05/2021)
- EMA press briefing to update on analysis of data on Vaxzevria, the COVID-19 vaccine from AstraZeneca (23/04/2021)
- Press briefing on PRAC conclusions on signal of thromboembolic events with COVID-19 Vaccine Janssen (20/04/2021)
- Press briefing on the conclusion of the assessment of the Pharmacovigilance Risk Assessment Committee (PRAC) of Vaxzevria (previously COVID-19 Vaccine AstraZeneca) and thromboembolic events (07/04/2021)
- Press briefing on the conclusion of the investigation of COVID-19 Vaccine AstraZeneca and thromboembolic events by the Pharmacovigilance Risk Assessment Committee (PRAC) (18/03/2021)
- Press briefing on EU recommendation for COVID-19 Vaccine AstraZeneca (29/01/2021)
- Press briefing on EU recommendation on first COVID-19 vaccine (21/12/2020)